Robert S Gaston1, Ann Fieberg2, Erika S Helgeson2, Jason Eversull1, Lawrence Hunsicker3, Bertram L Kasiske4, Robert Leduc2, David Rush5, Arthur J Matas6. 1. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL. 2. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN. 3. Department of Internal Medicine, University of Iowa, Iowa City, IA. 4. Division of Nephrology, Hennepin Healthcare, Minneapolis, MN. 5. Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. 6. Transplantation Division, Department of Surgery, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: About half of late kidney allograft losses are attributed to death with function (DWF), a poorly characterized outcome. An ongoing question is whether DWF is a consequence of chronic allograft dysfunction. Using the prospective Long-term Deterioration of Kidney Allograft Function study database, we sought to better define the impact, phenotype, and clinical course of DWF in the current era. METHODS: Three thousand five hundred eighty-seven kidney recipients with functional grafts at 90 days post-transplant were followed prospectively for a median of 5.2 years. RESULTS: Characteristics at transplantation in those with DWF (N = 350, 9.8%) differed from those who otherwise lost their grafts (death-censored graft failure [DC-GF], N = 295, 8.2%) or maintained function (N = 2942, 82.0%); DWF patients were older, sicker, and had been on dialysis longer, with more preexisting cardiovascular disease, whereas DC-GF patients experienced more early rejection, more acute rejection after 90 days, and a clinically significant decrease in kidney function before graft failure. In contrast, the clinical course after transplantation in DWF patients did not differ before death from those who maintained function throughout. CONCLUSIONS: DWF and DC-GF in kidney transplant recipients represent differing clinical phenotypes occurring in distinct patient populations. Reducing the impact of DWF requires better definition of causes and clinical course and then trials of therapies to improve outcomes. Composite endpoints in clinical trials that group DWF and DC-GF together may obscure important clinical findings.
BACKGROUND: About half of late kidney allograft losses are attributed to death with function (DWF), a poorly characterized outcome. An ongoing question is whether DWF is a consequence of chronic allograft dysfunction. Using the prospective Long-term Deterioration of Kidney Allograft Function study database, we sought to better define the impact, phenotype, and clinical course of DWF in the current era. METHODS: Three thousand five hundred eighty-seven kidney recipients with functional grafts at 90 days post-transplant were followed prospectively for a median of 5.2 years. RESULTS: Characteristics at transplantation in those with DWF (N = 350, 9.8%) differed from those who otherwise lost their grafts (death-censored graft failure [DC-GF], N = 295, 8.2%) or maintained function (N = 2942, 82.0%); DWF patients were older, sicker, and had been on dialysis longer, with more preexisting cardiovascular disease, whereas DC-GF patients experienced more early rejection, more acute rejection after 90 days, and a clinically significant decrease in kidney function before graft failure. In contrast, the clinical course after transplantation in DWF patients did not differ before death from those who maintained function throughout. CONCLUSIONS: DWF and DC-GF in kidney transplant recipients represent differing clinical phenotypes occurring in distinct patient populations. Reducing the impact of DWF requires better definition of causes and clinical course and then trials of therapies to improve outcomes. Composite endpoints in clinical trials that group DWF and DC-GF together may obscure important clinical findings.
Authors: Anita Borski; Alexander Kainz; Nicolas Kozakowski; Heinz Regele; Johannes Kläger; Robert Strassl; Gottfried Fischer; Ingrid Faé; Sabine Wenda; Željko Kikić; Gregor Bond; Roman Reindl-Schwaighofer; Katharina A Mayer; Michael Eder; Markus Wahrmann; Susanne Haindl; Konstantin Doberer; Georg A Böhmig; Farsad Eskandary Journal: Front Med (Lausanne) Date: 2022-04-21
Authors: Christian Kjellman; Angela Q Maldonado; Kristoffer Sjöholm; Bonnie E Lonze; Robert A Montgomery; Anna Runström; Tomas Lorant; Niraj M Desai; Christophe Legendre; Torbjörn Lundgren; Bengt von Zur Mühlen; Ashley A Vo; Håkan Olsson; Stanley C Jordan Journal: Am J Transplant Date: 2021-07-19 Impact factor: 9.369
Authors: Massini A Merzkani; Andrew J Bentall; Byron H Smith; Xiomara Benavides Lopez; Matthew R D'Costa; Walter D Park; Walter K Kremers; Naim Issa; Andrew D Rule; Harini Chakkera; Kunam Reddy; Hasan Khamash; Hani M Wadei; Martin Mai; Mariam P Alexander; Hatem Amer; Aleksandra Kukla; Mireille El Ters; Carrie A Schinstock; Manish J Gandhi; Raymond Heilman; Mark D Stegall Journal: Transplant Direct Date: 2022-01-13
Authors: Alaa Abbas Ali; Safaa E Almukhtar; Kais H Abd; Zana Sidiq M Saleem; Dana A Sharif; Michael D Hughson Journal: BMC Nephrol Date: 2021-08-07 Impact factor: 2.388